Gabriel Yariv, Executive Director of Cannabics Pharmaceuticals and Dr. David Sans will participate at the ICDP Summit in Boston

On September 22, 2021 Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a global leader in the development of cancer related cannabinoid-based medicine, reported that the Company will present at the 4th Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston (Press release, Cannabics Pharmaceuticals, SEP 22, 2021, View Source [SID1234590540]). Our team will be participating along with others from across the cannabinoid research and drug development space, including industry and academic experts from major pharmaceutical companies, biotech firms, and world leading universities.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Gabriel Yariv, company President and COO said: "The Cannabinoid Derived Pharmaceuticals Summit in Boston is the world largest conference exclusively devoted to CDP for medical conditions using FDA/EMA approval regularly pathways and with focus on clinical trials across the world and we are honored and proud to have been invited to participate at this 2021 4th Edition in Boston."

Eyal Barad, Cannabics Pharmaceuticals’ Co-founder and CEO commented: "The remarkable success of cannabinoids being approved today is just the beginning and we are excited to participate at the Cannabinoid Derived Pharmaceuticals Summit."

Read more:

Recent expansion of Cannabics Pharmaceuticals’ Board of Advisors to include: Prof. Caroline Robert (MD, Ph.D.), a Melanoma expert, and, Dr. Sigal Tavor (MD), a Hematology expert, along with Prof. Amos Toren (MD), Prof. Zamir Halpern (MD), Prof. Noam Shomron (Ph.D.), Dr. Erez Scapa (MD), Dr. Dana Ben-Ami Shor (MD), Dr. Sigalit Arieli-Portnoy (Ph.D.) and Dr. Tal Mofkadi (Ph.D.).

Recent expansion of Cannabics Pharmaceuticals’ Board of Directors to include: Dr. Inbar Maymon-Pomeranchik (Ph.D.), and Dr. Gil Feiler (Ph.D.) as Independent Directors.